NASDAQ:ANDS - Anadys Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Anadys Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing medicines for the treatment of hepatitis C. The Company is focusing on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway for the treatment of hepatitis C. In January 2011, the Company initiated a Phase IIb clinical study of ANA598 in combination with SOC for the treatment of hepatitis C. In the Phase IIb study, approximately 200 chronically infected genotype 1 hepatitis C patients are to receive ANA598 200 mg bid in combination with standard of care (SOC), with a loading dose of 800 mg ANA598 bid on day one. In addition, approximately 66 chronically infected genotype 1 hepatitis C patients are to receive placebo added to SOC. Receive ANDS News and Ratings via Email Sign-up to receive the latest news and ratings for ANDS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:ANDS Previous Symbol CUSIPN/A Webwww.anadyspharma.com Phone+1-858-5303600Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A OptionableNot Optionable Anadys Pharmaceuticals (NASDAQ:ANDS) Frequently Asked Questions What is Anadys Pharmaceuticals' stock symbol? Anadys Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANDS." Has Anadys Pharmaceuticals been receiving favorable news coverage? Press coverage about ANDS stock has trended very positive on Tuesday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Anadys Pharmaceuticals earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. How do I buy shares of Anadys Pharmaceuticals? Shares of ANDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Anadys Pharmaceuticals' official website? The official website for Anadys Pharmaceuticals is http://www.anadyspharma.com/. How can I contact Anadys Pharmaceuticals? Anadys Pharmaceuticals' mailing address is Suite 200, 5871 Oberlin Drive, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-5303600. MarketBeat Community Rating for Anadys Pharmaceuticals (NASDAQ ANDS)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 52 (Vote Outperform)Underperform Votes: 75 (Vote Underperform)Total Votes: 127MarketBeat's community ratings are surveys of what our community members think about Anadys Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANDS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2019 by MarketBeat.com StaffFeatured Article: Why are analyst ratings important in trading stocks?